Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Evaluation of Antihyperlipidemic Potential of Drakshasava Prepared by Traditional and Modern Methods in Hyperlipidemic Rats


Affiliations
1 Head of Department of Pharmacognosy and Phytochemistry, IIMT College of Medical Sciences, Meerut, (U.P.), India
2 Head of Department of Pharmacognosy, Shri S. K. Patel College of Pharmaceutical Education and Research, Kherva-382711, Gujarat, India
     

   Subscribe/Renew Journal


The objective of the present study was to evaluate the lipid peroxidation activity and related antihyperlipidemic activity of Drakshasava-T and Drakshasava-M prepared by traditional and modern methods and its marketed formulation in high fat diet induced hyperlipidemic rats. The antioxidant activity of Drakshasava-T and Drakshasava-M was increased in concentration dependent manner. Drakshasava-T and Drakshasava-M inhibited the ferrous sulphate induced lipid peroxidation in a dose dependent manner and showed inhibitory concentration (IC50) value 212.50 and 220.15 μg/ml respectively. Oral administration of Drakshasava-T and Drakshasava- M for nine weeks at the dose of 2 ml/kg significantly reduced serum cholesterol, serum LDL and serum triglycerides while showed significant rise in serum HDL as compared to high fat diet fed control group. Marketed Drakshasava also showed significant decrease in serum cholesterol, serum LDL, serum triglycerides and showed significant rise in serum HDL. Atorvastatin (1.2 mg/kg, p.o.) was used as standard antihyperlipidemic drug. Both types of Drakshasava as Drakshasava-T and Drakshasava-M showed significant reduction in atherogenic index as compared to high fat diet fed control group which strongly supports antiatherosclerotic property of Drakshasava.

Keywords

Drakshasava, Lipid per Oxidation, Atherogenic Index, Antihyperlipidemic Activity, Atorvastatin
Subscription Login to verify subscription
User
Notifications
Font Size


  • Tripathi. K.D .Essentials of Medical Pharmacology. 4th Edition, published by Jaypee Brothers, New Delhi, 2002; 612-614.

  • Singh N, Kapur KK and Singh SP. Mechanism of cardiovascular action of Terminalia arjuna . J Med Plant Res. 1982; 45:102-104.

  • The Ayurvedic Formulary of India, Part-II, 2000, 1st edition, The Controller of Publications, Delhi, p.35.

  • Baydar NG, Ozkan G, Sagdic O. Total phenolic contents and antibacterial activities of grape (Vitis vinifera L.) extracts. Food Control 2004; 15:335-339.

  • Akoh CC, Bonilla EP, Sellappan S, Krewer G. Phenolic content and antioxidant capacity of Muscadine grapes. Journal of Agricultural and Food Chemistry 2003; 51:5497-5503.

  • Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. The Lancet 1993; 341(20):454- 457.

  • Mayer AS, Yi OS, Person DA, Waterhouse DL, Frankel EN. Inhibition of human low density lipoprotein oxidation in relation to composition of phenolic antioxidants in grapes (Vitis vinifera). Journal of Agricultural and Food Chemistry 1997; 45:1638-1643.

  • Teissedre PL, Frankel EN, Waterhouse AL, Peleg H, German GB. Inhibition of in vitro human LDL oxidation by phenolic antioxidants from grapes and wines. Journal of the Science of Food and Agriculture 1996; 70:55-61.

  • Waterhouse AL. Wine antioxidants may reduce heart disease and cancer. Presentation of American Chemical Society, Washington; 1994.

  • Renaud S, Lorgeril MD. Wine, alcohol, platelets and the French paradox for coronary heart disease. The Lancet 1992; 339:1523- 1526.

  • Davalos A, Bortolome B, Gomez-cordoves C. Antioxidant properties of commercial grape juices and vinegars. Food Chemistry 2005; 93(2):325-330.

  • Orhan DD, Orhan N, Ergun E, Ergun F. Hepatoprotective effect of Vitis vinifera L. leaves on carbon tetrachloride-induced acute liver damage in rats. Jornal of Ethnopharmacology 2007; 112:145-151.

  • Corder R, Mullen W, Khan NQ, Marks SC, Wood EG, Carrier MJ, Crozier A. Red wine procyanidins and vascular health. Nature 2006;444:566.

  • Mishra S. Bhaisazya Kalpana Vigyan. Varanasi, India: Chaukambha Surbharati Prakashan; 2005.p. 253-254.

  • Alam M, Radhamani S, Ali U, Purushottam KK. Microbiological Screening of Dhataki Flowers. Journal of Research in Ayurveda and Siddha 1984; 2(4):371-375.

  • Braugghler JM, Duncan CA and Chase IR. The involvement of iron in lipid peroxidation. J Biol Chem. 1986; 261(22): 10282- 89.

  • Lowery OH, Rosenbrough NJ, Farr AL and Randall RJ. Protein estimation with Folin phenol reagent. Biol Chem. 1951;193:265-275.

  • Khanna AK, Chander R and Kapoor NK. Terminala arjuna: an Ayurvedic cardiotonic, Regulates lipid metabolism in Hyperlipidemic rats. Phytother Res. 1996;10: 663-665.

  • Allain CC, Poon LS, Chan CS and Richmond W. Enzymatic Determination of Total Serum cholesterol. Clin Chem .1974;20::447-475.

  • Friedewald WT, Levy RI and Fredrickson DS. Estimation of concentration of low density cholesterol in plasma without use of ultracentrifuge. J Clin Chem .1972;18: 449-502.

  • Muller PH, Schmulling RM, Liebich HM and Eggstein M. A fully Enzymatic Triglyceride Determination. J Clin Chem. 1977;15:457-464.

  • Anne SM, Ock SY, Debra AP, Andrew LW and Edwin NF. Inhibition of Human Low Density Lipoprotein oxidation in relation to composition of Phenolic antioxidants in Grapes (Vitis Vinifera). J Agri Food Chem. 1997;45 (5):1638-1643.

  • S Renaud, and M De Lorgeril. Wine, alcohol, Platelets and the French Paradox for Coronary Heart Disease. The Lancet. 1992; 339: 1523-1526.

  • Pederson TR. Low- density lipoprotein cholesterol lowering is and will be the key to the future of lipid management. American J Cardiol. 2001; 87(5A): 8B-12B.

  • Boden WE and Pearson TA. Raising low levels of High Density Lipoprotein Cholesterol is an important target of therapy. American J cardiol. 2000; 85(5):645-650.


Abstract Views: 653

PDF Views: 2




  • Evaluation of Antihyperlipidemic Potential of Drakshasava Prepared by Traditional and Modern Methods in Hyperlipidemic Rats

Abstract Views: 653  |  PDF Views: 2

Authors

Preeti Tiwari
Head of Department of Pharmacognosy and Phytochemistry, IIMT College of Medical Sciences, Meerut, (U.P.), India
Rakesh K. Patel
Head of Department of Pharmacognosy, Shri S. K. Patel College of Pharmaceutical Education and Research, Kherva-382711, Gujarat, India

Abstract


The objective of the present study was to evaluate the lipid peroxidation activity and related antihyperlipidemic activity of Drakshasava-T and Drakshasava-M prepared by traditional and modern methods and its marketed formulation in high fat diet induced hyperlipidemic rats. The antioxidant activity of Drakshasava-T and Drakshasava-M was increased in concentration dependent manner. Drakshasava-T and Drakshasava-M inhibited the ferrous sulphate induced lipid peroxidation in a dose dependent manner and showed inhibitory concentration (IC50) value 212.50 and 220.15 μg/ml respectively. Oral administration of Drakshasava-T and Drakshasava- M for nine weeks at the dose of 2 ml/kg significantly reduced serum cholesterol, serum LDL and serum triglycerides while showed significant rise in serum HDL as compared to high fat diet fed control group. Marketed Drakshasava also showed significant decrease in serum cholesterol, serum LDL, serum triglycerides and showed significant rise in serum HDL. Atorvastatin (1.2 mg/kg, p.o.) was used as standard antihyperlipidemic drug. Both types of Drakshasava as Drakshasava-T and Drakshasava-M showed significant reduction in atherogenic index as compared to high fat diet fed control group which strongly supports antiatherosclerotic property of Drakshasava.

Keywords


Drakshasava, Lipid per Oxidation, Atherogenic Index, Antihyperlipidemic Activity, Atorvastatin

References